Abstract
Background
Little is known about the cost-effectiveness of secondary prevention after percutaneous coronary intervention (PCI). The aim of this study was to estimate the cost-effectiveness of statin therapy.
Methods
A cost-effectiveness analysis was performed using data from the Lescol Intervention Prevention Study (LIPS). In the LIPS trial, patients with normal-to-moderate hypercholesterolaemia who had undergone a first PCI were randomised to receive either fluvastatin 40 mg twice-daily plus dietary counselling or dietary counselling alone. A Markov model was used to estimate the incremental costs per quality-adjusted life year (QALY) and life year gained (LYG). Costs were based on prices and reimbursed charges, utility data were drawn from literature. Monte Carlo simulations and multivariate analysis were used to assess uncertainty.
Results
Routine statin treatment costs an additional €734 (SD €686) per patient over ten years compared with controls. It resulted in an additional 0.078 (0.047) QALYs or 0.082 (0.041) LYG. The incremental costs per QALY and LYG were €9312 (€14,648) and €8954 (€16,617) respectively. Anticipating a willingness to pay of €20,000 per QALY, there is a 75.1% chance that fluvastatin treatment is cost-effective.
Conclusion
Statin therapy with fluvastatin is economically efficient with regard to reducing heart disease in the Netherlands when given routinely to all patients following PCI.
Keywords: cardiac events, cost-effectiveness, fluvastatin, secondary prevention, statins
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7–22. doi: 10.1016/S0140-6736(02)09327-3. [DOI] [PubMed] [Google Scholar]
- Huse D. M., Russell M. W., Miller J. D., Kraemer D. F., D'Agostino R. B., Ellison R. C., Hartz S. C. Cost-effectiveness of statins. Am J Cardiol. 1998 Dec 1;82(11):1357–1363. doi: 10.1016/s0002-9149(98)00641-9. [DOI] [PubMed] [Google Scholar]
- Melsop Kathryn A., Boothroyd Derek B., Hlatky Mark A. Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J. 2003 Jan;145(1):36–41. doi: 10.1067/mhj.2003.37. [DOI] [PubMed] [Google Scholar]
- Prosser L. A., Stinnett A. A., Goldman P. A., Williams L. W., Hunink M. G., Goldman L., Weinstein M. C. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000 May 16;132(10):769–779. doi: 10.7326/0003-4819-132-10-200005160-00002. [DOI] [PubMed] [Google Scholar]
- Ruygrok P. N., de Jaegere P. T., van Domburg R. T., van den Brand M. J., Serruys P. W., de Feyter P. J. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients. J Am Coll Cardiol. 1996 Jun;27(7):1669–1677. doi: 10.1016/0735-1097(96)00046-0. [DOI] [PubMed] [Google Scholar]
- Scuffham Paul A., Chaplin Stephen. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. Pharmacoeconomics. 2004;22(8):525–535. doi: 10.2165/00019053-200422080-00004. [DOI] [PubMed] [Google Scholar]
- Serruys Patrick W. J. C., de Feyter Pim, Macaya Carlos, Kokott Norbert, Puel Jacques, Vrolix Matthias, Branzi Angelo, Bertolami Marcelo C., Jackson Graham, Strauss Bradley. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002 Jun 26;287(24):3215–3222. doi: 10.1001/jama.287.24.3215. [DOI] [PubMed] [Google Scholar]
- Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
- van Hout B. A., Al M. J., Gordon G. S., Rutten F. F. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994 Sep-Oct;3(5):309–319. doi: 10.1002/hec.4730030505. [DOI] [PubMed] [Google Scholar]